Alternative treatment of psoriasis - is rifampicin a mild immunosupressor? / Alternativna terapija psorijaze: da li rifampicin ima blago imunosupresivno dejstvo?

1.Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.10.1067/mjd.2002.120568Search in Google Scholar

2. Prinz LC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70.10.1046/j.1468-3083.2003.00720.xSearch in Google Scholar

3. Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007;156(6):1245-50.10.1111/j.1365-2133.2007.07881.xSearch in Google Scholar

4. Thaci D. Long-term data in the treatment of psoriasis. Br J Dermatol 2008;159(Suppl 2):18-24.10.1111/j.1365-2133.2008.08781.xSearch in Google Scholar

5. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for the treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.10.1016/j.jaad.2008.02.040Search in Google Scholar

6. Tsankov N, Krasteva M. Rifampin in severe forms of psoriasis. J Dermatol Treat 1992;3:69-71.10.3109/09546639209089062Search in Google Scholar

7. Tsankov NK, Kamarashev JA. Rifampin in dermatology. Int J Dermatol 1993;32:401-6.10.1111/j.1365-4362.1993.tb02807.xSearch in Google Scholar

8. Tsankov N, Krasteva M. On rifampin treatment of psoriasis (letter). J Am Acad Dermatol 1993;29(6): p. 1057.10.1016/S0190-9622(08)82050-6Search in Google Scholar

9. Kazandjieva J, Kamarashev J, Hinkov G. Alleviation of psoriasis by rifampicin treatment of pulmonary tuberculosis(letter). J Dermatol Treat 1993;4:163-5Search in Google Scholar

10. Kzandjieva J, Kamarashev J, Hinkov G, Tsankov N. Rifampicin und Psoriasis. Aktuel Dermatol 1997;23:78-81.Search in Google Scholar

11. Tsankov N. Drug therapy in patients with Psoriasis vulgaris: risks and perspectives (dissertation). Sofian (Bulgaria): Medical University; 1996.Search in Google Scholar

12. Grozdev I, Kazandjieva J, Tsankov N. Rifampicin in eruptive psoriasis (abstract). J Eur Acad Dermatol Venereol 2004;18(Suppl 1):57-8Search in Google Scholar

13. Grozdev I, Kazndjieva J, Tsankov N. Use of rifampicin for the treatment of psoriasis (abstract). J Eur Acad Dermatol Venereol 2004;18(Suppl 2):268-9.Search in Google Scholar

14. Tsankov N, Kazandjieva J, Grozdev I. Treatment of psoriasis with rifampicin. Is rifampicin an immunosuppressive antibiotic? (poster presentation). European Congress on Psoriasis; 2004 Oct 21-24; Paris, France. Paris: European Academy of Dermatology and Venerology; 2004.Search in Google Scholar

15. Tsankov N, Grozdev I. Rifampicin as treatment strategy for psoriasis: benefits and risks (oral presentation); The 2^nd International Congress on Psoriasis; 2007 June 21-24; Paris, France. Paris: European Academy of Dermatology and Venerology; 2007.Search in Google Scholar

16. Tsankov N, Grozdev I, Kazandjieva J. Old drug: new indication. Rifampicin in psoriasis. J Dermatol Treat 2006;17(1):18-23.10.1080/0954663050037564316467019Search in Google Scholar

17. Tsankov N, Grozdev I. Rifampicin in treatment of psoriasis. J Eur Acad Dermatol Venereol 2009;23(1):93-5.10.1111/j.1468-3083.2008.02721.x18384550Search in Google Scholar

18. Farber EM, Nall L. Guttate psoriasis. Cutis 1993;51:157-64.Search in Google Scholar

19. Yamamoto T, Katayama I, Nishioka K. Clinical analysis of staphylococcal superantigen hyper-reactive patients with psoriasis vulgaris. Eur J Dermatol 1998;8:325-9.Search in Google Scholar

20. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens. Immunol Today 1995;16:145-9.10.1016/0167-5699(95)80132-4Search in Google Scholar

21. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 1995; 181:747-53.10.1084/jem.181.2.747Search in Google Scholar

22. Paunescu E. In vivo and in vitro suppression of humoral and cellular response by rifampicin. Nature 1970;229:1188-9.10.1038/2281188a0Search in Google Scholar

23. Nilsson BS. Rifampicin: an immunosuppressant? Lancet 1971;2:374.Search in Google Scholar

24. Gupta S, Grieco MH, Siegel I. Suppression of T-lymphocyte rosettes by Rifampicin: studies in normals and patients with tuberculosis. Ann Intern Med 1975;82:484-8.10.7326/0003-4819-82-4-484Search in Google Scholar

25. Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int Immunopharmacol 2003;3:513-22.10.1016/S1567-5769(03)00022-5Search in Google Scholar

26. Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother 2004;16:357-61.10.1179/joc.2004.16.4.357Search in Google Scholar

27. Calleja C, Pascussi JM, Mani JC, et al. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 1998;4:92-6.10.1038/nm0198-092Search in Google Scholar

28. Dubrac S, Elentner A, Ebner S, Horejs-Hoeck J, Schmuth M. Modulation of T-lymphocyte function by the Pregnane X Receptor (PXR). J Immunol 2010;184(6):2949-57.10.4049/jimmunol.0902151Search in Google Scholar

29. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5:S440-6.10.1093/clinids/5.Supplement_3.S440Search in Google Scholar

30. Scheuer PJ, Summerfield JA, Lal S, et al. Rifampin hepatitis. Lancet 1974;1:421-5.10.1016/S0140-6736(74)92381-2Search in Google Scholar

31. Girling DJ, Hitze HL. Adverse reactions to rifampicin. Bull WHO 1979;57:45-9.Search in Google Scholar

32. O’Reilly RA. Interaction of chronic daily warfarin and rifampin. Ann Intern Med 1975;83:506-8. 10.7326/0003-4819-83-4-5061166982Search in Google Scholar